Where Will Windtree Therapeutics Inc (WINT) Stock Go Next After It Is Up 8.26% in a Week?

The market has been neutral on Windtree Therapeutics Inc (WINT) stock recently. WINT gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Windtree Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on WINT!

See Full WINT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With WINT Stock Today?

Windtree Therapeutics Inc (WINT) stock is trading at $1.31 as of 10:24 AM on Monday, Oct 16, a gain of $0.06, or 4.8% from the previous closing price of $1.25. The stock has traded between $1.27 and $1.36 so far today. Volume today is less active than usual. So far 26,548 shares have traded compared to average volume of 125,561 shares. To screen for more stocks like Windtree Therapeutics Inc click here.

More About Windtree Therapeutics Inc

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products. Click Here to get the full Stock Report for Windtree Therapeutics Inc stock.